Drug Database
BR

bronchitis vaccine

✓ Approved

China National Pharmaceutical · 细胞治疗 · 细胞治疗

什么是 bronchitis vaccine?

bronchitis vaccine 是一种细胞治疗,由China National Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

公司China National Pharmaceutical
药物类别细胞治疗, 疫苗
给药途径Unknown
状态Approved

治疗适应症

bronchitis vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersBronchitis chronic✓ Approved

相关研究文献

PubMedRespiratory research2026-11-19

Association between sodium-glucose cotransporter 2 inhibitors and the risk of chronic lower respiratory disease in type 2 diabetes mellitus: findings from two target trial emulations.

Li Yuhao Y, Lv Yiqiao Y, Dai Yongqi Y, Zeng Huatang H et al.

Research on the association between sodium‑glucose cotransporter 2 inhibitors (SGLT-2i) and chronic lower respiratory diseases (CLRDs) in patients with type 2 diabetes (T2DM) remains limited. This study aimed to investigate this association and examine the potential modifying effects such as age, sex, and diabetes severity. Using the Shenzhen Public Health Data Platform, we conducted two independent target trial emulations with a new‑user active comparator design, comparing SGLT‑2i with glucagon‑like peptide‑1 receptor agonists (GLP-1RA) and dipeptidyl peptidase‑4 inhibitors (DPP‑4i), respectively. The primary outcome was incident CLRD; secondary outcomes included five subtypes-bronchitis, bronchiectasis, asthma, chronic obstructive pulmonary disease, and emphysema. Overlap-weighted Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). During a median follow-up of 1.76 years, 349 (7.95%) and 397 (9.04%) new CLRD cases occurred in SGLT-2i and GLP-1RA users, respectively. Compared with GLP-1RA, SGLT-2i use was associated with a lower CLRD incidence (HR 0.87, 95% CI 0.79-0.96), primarily driven by reduced risk of bronchitis (HR: 0.89; 95% CI: 0.79-1.00) and asthma (HR: 0.77; 95% CI: 0.58-1.01); no significant associations were found for other subtypes. Compared with DPP-4i, SGLT-2i use showed a trend toward lower CLRD risk (HR: 0.95; 95% CI: 0.91-0.99), with significant reductions for bronchitis (HR: 0.95; 95% CI: 0.91-1.00), bronchiectasis (HR: 0.86; 95% CI: 0.75-1.00), and asthma (HR: 0.87; 95% CI: 0.77-0.98). Subgroup analyses indicated significant interactions for bronchiectasis by sex (P interaction = 0.001). Compared with GLP-1 RA, SGLT-2i were associated with a significantly lower risk of CLRDs, driven predominantly by bronchitis; versus DPP-4i, the risk reduction was primarily observed for bronchitis, bronchiectasis, and asthma. The protective association between SGLT-2i use and bronchiectasis was more pronounced in females than in males relative to DPP-4i.

PMID 43053103
阅读全文 →
PubMedMycotoxin research2026-11-19

Biological mycotoxin d​etoxification in dried fruits: food safety challenges and barriers to industrial translation.

Qala Kaoutar K, Abdelmoumen Hanaa H

Despite decades of research demonstrating the detoxification potential of microorganisms and enzymes, biological mycotoxin detoxification has achieved only limited industrial implementation, particularly in dried fruits. This persistent gap between laboratory efficacy and practical application remains one of the major unresolved challenges in the field. Rather than providing another descriptive overview of detoxification mechanisms or biological agents, this critical narrative review examines the scientific, technological, regulatory, and commercial barriers limiting industrial translation. A structured literature search was conducted in Scopus, Web of Science, PubMed/MEDLINE, ScienceDirect, and Google Scholar, supplemented by screening the reference lists of relevant publications. Studies were selected according to their relevance to biological mycotoxin reduction, the mechanisms demonstrated, the food matrices investigated, and their implications for safety and industrial applicability, with priority given to publications from 2020 onward. The review highlights a substantial gap between reported laboratory efficacy and demonstrated applicability to dried fruits, as much of the available evidence derives from culture media, simplified food models, or other matrices, including cereals and feed. The low water activity and high sugar content of dried fruits further complicate the transfer of findings from other food systems. Additional barriers include reversible toxin adsorption, insufficient toxicological characterization of transformation products, methodological heterogeneity, limited process robustness, scale-up challenges, regulatory uncertainty, and economic feasibility. Advancing industrial implementation requires matrix-specific validation in naturally contaminated dried fruits under realistic processing and storage conditions, standardized assessment of detoxification mechanisms, and evidence that toxin reduction translates into a demonstrable decrease in toxicological risk. This review identifies research priorities to support the development of safe, scalable, and economically viable biological interventions for dried-fruit processing.

PMID 43052622
阅读全文 →
PubMedWellcome open research2026-11-19

Did the emergence of the Omicron variant impact the COVID-19 vaccine acceptance in the Arab world? A Twitter-based sentiment analysis.

Dimashkieh Chehab Nada N

Low vaccine acceptance constitutes a major obstacle for achieving herd immunity against coronavirus disease 2019 (COVID-19). Data on COVID-19 show a significant rise in the number of cumulative cases in Arab countries where vaccine uptake is lower than the uptake at the global level for the 2021-2022 period. The aim of this study is to analyze sentiments related to vaccine acceptance before and after the emergence of the COVID-19 Omicron variant in the Arab-speaking world. Tweets were collected before and after the Omicron emergence period in the Arab-speaking world using Python-enabled CAMeL Tools (Arabic Natural Language Processing toolkit) libraries. A sentiment analysis on COVID-19 vaccines using Arabic hashtags and a sentiment analysis by city were conducted. Two data sets pre-Omicron and post-Omicron tweets exhibited a difference in sentiments marking a shift towards less negativity and more neutrality. Sentiments by city showed most tweets in both periods coming from Riyadh and Jeddah in Saudi-Arabia, and from Salt in Jordan. Despite the limitations of the study, the change in sentiments detected by the study may suggest more vaccine acceptance which raises some hope and perhaps a higher vaccine uptake in the future. The sentiments by city findings may help in the design of future research.

PMID 43053887
阅读全文 →
PubMedNPJ vaccines2026-11-19

SARS-CoV-2 RBD fusion ameliorates enhanced disease induced by RSV G CCD mRNA vaccine in BALB/c mice.

Sun Yufang Y, Xie Ying Y, Liu Lian L, Yang Huijie H et al.

Respiratory syncytial virus (RSV) is a primary pathogen responsible for lower respiratory tract infections in both infants and the elderly. However, vaccine development has been consistently hampered by the risk of vaccine-enhanced disease (VED), while the role of the RSV attachment (G) glycoprotein has long been overlooked. Using an mRNA vaccine platform, this study systematically evaluated the roles of two critical RSV G protein domains-the central conserved domain (CCD) and the mucin-like domains-in mediating immune protection and VED. Results indicate that the mucin-like domains confer no protection and induce marked VED. Surprisingly, although CCD immunization elicits potent humoral immunity and significantly reduces viral load, it also induces Th2-biased responses and exacerbates pulmonary inflammation following RSV challenge. However, fusion of CCD with the receptor-binding domain (RBD) of SARS-CoV-2 in an mRNA vaccine (CCD + RBD) successfully redirected the Th2-biased immune responses toward a balanced Th1/Th2 profile, while significantly attenuating CCD-induced immunopathology. CD8⁺ T-cell depletion and adoptive-transfer experiments further supported a contribution of RBD-responsive CD8⁺ T cells to the reduction in pathology. These findings provide proof of concept that heterologous antigen fusion can reshape CCD-associated immunopathology in a BALB/c RSV challenge model.

PMID 43052326
阅读全文 →
PubMedNPJ vaccines2026-11-19

Efficacy, safety, and biodistribution of intranasally delivered adenoviral COVID-19 vaccine in hamsters.

Laham-Karam N N, Mäkinen P P, Koivulehto E E, Gurzeler E E et al.

Coronavirus disease 2019 (COVID-19) continues to cause outbreaks around the world despite the vast COVID-19 vaccination programs. Thus, it is important to continue developing better vaccines to protect vulnerable populations. Here, we studied the efficacy, safety, persistence and biodistribution of an adenovirus-based COVID-19 vaccine delivered intranasally. Our results confirmed that mucosal delivery leads to effective protection against infection in hamsters. A comparative study of different adenoviral vectors demonstrated that specifically Ad5-S-3M, expressing the SARS-CoV-2 spike glycoprotein ectodomain with inclusion of three common receptor binding domain mutations, induced a robust humoral immune response and effectively protected hamsters from SARS-CoV-2 infection. In addition, longitudinal analysis of vaccinated hamsters' tissues demonstrated durable vaccine transgene expression and persistent vector DNA in the nasal turbinates. This persistence may be beneficial in increasing the duration of immunity. Expression of the S-3M did not cause any aberrant changes in the hamster tissues and resulted in very few changes in cellular mRNA expression in target tissues. Safety and biodistribution assessment demonstrated restricted non-target tissue distribution of intranasally delivered vector and no significant changes in clinical blood chemistry, underlining the safety of the vaccine. These results further support that intranasal delivery is a promising approach for mucosal vaccine administration against respiratory infection pathogens and extend our knowledge of Adeno-vector persistence.

PMID 43052363
阅读全文 →
PubMedNPJ vaccines2026-11-19

Influenza neuraminidase as adjuvanted protein or mRNA vaccine protects mice against influenza A and B virus challenge.

Portela Catani João Paulo JP, Smet Anouk A, Ysenbaert Tine T, Amelinck Laura L et al.

Neuraminidase (NA) is an underutilized influenza vaccine antigen despite its recognized contribution to protective immunity. Here, we compared the immunogenicity and protective potential of multiple NA antigens delivered as an adjuvanted recombinant tetrameric protein or as mRNA-LNP encoding full-length NA in naïve mice. Both vaccine types induced robust neuraminidase-inhibiting (NAI) antibody responses and conferred protection to mice challenged with antigenically homologous influenza A or B viruses. However, only immunization with NA-encoding mRNA-LNP protected against challenge with a heterologous HxN2 virus, whereas immunization with recombinant NA was associated with earlier onset of weight loss following heterologous HxN2 virus challenge. Passive transfer of immune serum revealed that protection induced by mRNA immunization can be transferred by serum, and that early onset of weight loss is not induced by recombinant NA-derived sera; on the contrary, partial protection is achieved. Finally, NAI assays against a panel of antigenically distinct HxN2 viruses showed similar breadth of inhibition.

PMID 43052397
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bronchitis vaccine